Home' Australian Pharmacist : Australian Pharmacist April 2014 Contents Australian Pharmacist April 2014 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
COUNSELLING IN PRACTICE
1. Atopic dermatitis:
a) Is due to exogenous causes.
b) Usually occurs in patients over five years
c) Can occur within months of birth.
d) Is an atopic disease like asthma and type
2. Patients with atopic dermatitis:
a) Rarely suffer from flexural dermatitis.
b) Often experience itch.
c) Rarely experience dry skin.
d) Usually have no concerns about the use
of topical corticosteroids.
3. Topical corticosteroids:
a) Are the drugs of first choice for AD.
b) Inhibit the production of pro-
c) May reduce skin oedema.
d) All of the above.
a) Promotes function of calcineurin.
b) Plays no role in collagen synthesis.
c) Is not effective if there has been a
response to topical corticosteroids.
d) Is only effective when used long term.
5. Atopic dermatitis:
a) Can usually be cured.
b) Can have significant physical, mental
and emotional effects on children.
c) Can be more effectively treated by
certain complementary and alternative
d) Incidence and prevalence increase with
Is there any other useful
information about AD?
• There is currently no cure for AD.
However, both the incidence and
prevalence appear to decrease with
• Generalised AD can affect a child
and family to a similar degree as
having type 1 diabetes. Apart from
the well‐recognised comorbidities
of asthma, food allergy, allergic
rhinitis and a predisposition to
skin infections, children also may
experience significant psychosocial
and behavioural issues compared
with their peers.
• Conflicts between parents’
health beliefs and their child’s
actual health needs may present
significant challenges to healthcare
• Carers should be encouraged to try
different emollients because the
correct one is the one that the child
• Itchy skin can be rubbed but not
What is the pharmacist’s role in
Diagnosis is based on history and
, making AD a
problem uniquely suited to pharmacist
involvement. Aspects of diagnosis
outside the realm of pharmacists such
as procedural treatments, referrals
and pathology and imaging orders
by Australian GPs have been required
less often for eczema in general than
for other problems.
communication skills and time
commitment to explain disease state
management and correct use of
medicines, pharmacists may have the
ability to manage most cases of AD.
Before supplying pimecrolimus
cream, it would be desirable to ask
Mrs Scott how she has been treating
Sam. Reinforcement and reassurance
regarding appropriate treatment of AD
may result in the supply of pimecrolimus
cream being deferred. Her history of
emollient use, topical corticosteroid use
and environmental irritant management
plan should be investigated
Reducing immune and barrier
dysfunction and minimising exposure
to environmental irritants are the key
features of treatment for AD.
Knowledge, pro‐activity, empathy and
communication skills of the healthcare
professional may result in the best
outcome for carers and patients with AD.
1. Dermatitis [revised Feb 2009]. In: eTG complete.
Melbourne: Therapeutic Guidelines; 2013. At: www.tg.org.
2. Charles J, Pan Y, Miller G. Eczema. Aust Fam Physician
3. Magin PJ, Adams J, Heading GS, Pond CD. Patients with
skin disease and their relationships with their doctors:
a qualititative study of patients with acne, psoriasis and
eczema. MJA 2009;190:62–4 .
4. Smith SD, Stephens AM, Werren JC, Fischer GO. Treatment
failure in atopic dermatitis as a result of parental health
belief. MJA 2013(199):467–9 .
5. Chia A, Shumack S. Atopic dermatitis. Aust J Pharm
6. Carbone A, Siu A, Patel R. Pediatric atopic dermatitis: A
review of the medical management. Ann Pharmacother
7. Berke R, Singh A, Guralnick M. Atopic dermatitis: an
overview. Am Fam Physician 2012;86:35–42.
8. Kuo I-H, Yoshida T, De Benedetto A, Beck LA. The
cutaneous innate immune response in patients with
atopic dermatitis. J Allergy Clin Immunol 2013;131:266–78.
9. Sprecher E, Leung DYM. Atopic dermatitis: scratching
through the complexity of barrier dysfunction. J Allergy
Clin Immunol 2013;132:1130–1 .
10. McAleer M, Irvine A. The multifunctional role of
filaggrin in allergic skin disease. J Allergy Clin Immunol
11. Norris DA. Mechanisms of action of topical therapies
and the rationale for combination therapy. J Am Acad
12. Ridd M, Purdy S. Exacerbation of atopic eczema in
children. BMJ 2009;339:860–61.
13. Kalavala M, Dohil MA. Calcineurin inhibitors in pediatric
atopic dermatitis. Am J Clin Dermatol 2011;12:15–24.
14. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2013. At: www.amh.net.
15. Carlos G, Uribe P, Fernandez-Penas P. Rational use of
topical corticosteroids. Aust Prescr 2013;36:158–61.
16. Yaghmaie P, Koudelka CW, Simpson EL. Mental health
comorbidity in patients with atopic dermatitis. J Allergy
Clin Immunol 2013;131:428–33 .
Links Archive Australian Pharmacist March 2014 Australian Pharmacist May 2014 Navigation Previous Page Next Page